DA Hoestbruistabletten Acetylcysteïne
DA Hoestbruistabletten Acetylcysteïne Uses, Dosage, Side Effects, Food Interaction and all others data.
DA Hoestbruistabletten Acetylcysteïne has a mucolytic activity through its free sulfhydryl group. It acts directly on the mucoproteins to open the disulfide bonds and thus lowers the viscosity of the mucous and facilitates its removal by the muco-cillary action and expectoration. DA Hoestbruistabletten Acetylcysteïne improves the phagocytic capacity of the alveolar macrophages, thus protecting lungs from a variety of insults. DA Hoestbruistabletten Acetylcysteïne is a precursor to glutathione, the most important intra & extra-cellular antioxidant (the safest & most convenient)
DA Hoestbruistabletten Acetylcysteïne is indicated for mucolytic therapy and in the management of acetaminophen overdose. It has a short duration of action as it is given every 1-8 hours depending on route of administration, and has a wide therapeutic window. Patients should be counselled regarding diluting oral solutions in cola for taste masking, the risk of hypersensitivity, and the risk of upper gastrointestinal hemorrhage.
| Trade Name | DA Hoestbruistabletten Acetylcysteïne |
| Availability | Rx and/or OTC |
| Generic | Acetylcysteine |
| Acetylcysteine Other Names | (R)-mercapturic acid, Acetilcisteina, Acetylcysteine, Acetylcysteinum, L-acetylcysteine, Mercapturic acid, N-acetylcysteine |
| Related Drugs | biotin, Vitamin C, ascorbic acid, multivitamin, Zinc, Fish Oil, Mucinex DM, Robitussin Cough + Chest Congestion DM, dextromethorphan / guaifenesin, Tussin DM |
| Type | |
| Formula | C5H9NO3S |
| Weight | Average: 163.195 Monoisotopic: 163.030313849 |
| Protein binding | Acetylcysteine is 66-97% protein bound in serum, usually to albumin. |
| Groups | Approved, Investigational |
| Therapeutic Class | Antidote preparations, Cough expectorants & mucolytics |
| Manufacturer | |
| Available Country | Netherlands |
| Last Updated: | September 19, 2023 at 7:00 am |
Uses
DA Hoestbruistabletten Acetylcysteïne is used for an adjunctive treatment for patients with abnormal, viscid or inspissated mucus secretions associated with conditions such as-
Acute and chronic bronchopulmonary disorders (e.g. pneumonia, bronchitis, emphysema, tracheobronchitis, chronic asthmatic bronchitis, tuberculosis, bronchiectasis, primary amyloidosis of the lung) Atelectasis caused by mucus obstruction Pulmonary complications of cystic fibrosis Pulmonary complications of thoracic and cardiovascular surgery Post-traumatic chest conditions.
It is effective in all respiratory airways disease causing formation of a dense secretion that cannot be or can only partially be expectorated such as acute and chronic bronchitis, laryngitis, sinusitis, tracheitis, infuenza & bronchial asthma. DA Hoestbruistabletten Acetylcysteïne is also used for the treatment of Paracetamol overdose. Treatment option is optimal if given within 8 hours of Paracetamol ingestion.
DA Hoestbruistabletten Acetylcysteïne is also used to associated treatment for these conditions: Acetaminophen Overdose, Chronic Rhinitis, Corneal Diseases, Corneal ulceration, Crusting Rhinitis, Keratopathy, Rhinitis, Sinusitis, Vasomotor Rhinitis, Acute Rhinitis, Subacute Rhinitis, Airway secretion clearance therapy
How DA Hoestbruistabletten Acetylcysteïne works
A number of possible mechanisms for the mucolytic activity of acetylcysteine have been proposed. DA Hoestbruistabletten Acetylcysteïne's sulfhydryl groups may hydrolize disulfide bonds within mucin, breaking down the oligomers, and making the mucin less viscous. DA Hoestbruistabletten Acetylcysteïne has also been shown to reduce mucin secretion in rat models. It is an antioxidant in its own right but is also deacetylated to cysteine, which participates in the synthesis of the antioxidant glutathione. The antioxidant activity may also alter intracellular redox reactions, decreasing phosphorylation of EGFR and MAPK, which decrease transcription of the gene MUC5AC which produces mucin.
In the case of acetaminophen overdoses, a portion of the drug is metabolized by CYP2E1 to form the potentially toxic metabolite N-acetyl-p-benzoquinone imine (NAPQI). The amount of NAPQI produced in an overdose saturates and depletes glutathione stores. The free NAPQI promiscuously binds to proteins in hepatocytes, leading to cellular necrosis. DA Hoestbruistabletten Acetylcysteïne can directly conjugate NAPQI or provide cysteine for glutathione production and NAPQI conjugation.
Dosage
DA Hoestbruistabletten Acetylcysteïne dosage
DA Hoestbruistabletten Acetylcysteïne Tablet:
The dispersible tablet should be dissolved in 1/2 glass of water before use (preferably in the evening). The duration of treatment should be 5 to 10 days in the acute phase. It may be continued in the chronic state for up to 6 months or according to the advice of the physician.
As a mucolytic:
- Adults: 600 mg daily as a single dose.
- In Paracetamol overdose: Initially 140 mg/kg, followed by 70 mg/kg every 4 hours for an additional 17 doses. As an antidote, DA Hoestbruistabletten Acetylcysteïne is reported to be very effective when administered within 8 hours of Paracetamol overdose, with the protective effect diminishing after this time. Initiation of treatment after a lapse of 15 hours has previously been thought to be ineffective, but recent studies suggest that beneficial results may still be obtained.
DA Hoestbruistabletten Acetylcysteïne Respirator Solution:
The 20% solution may be diluted to a lesser concentration with either Sodium Chloride for injection, Sodium Chloride for inhalation, sterile water for injection, or sterile water for inhalation.
As a mucolytic:
Adult:
- 5-10 ml of 10% or 20% solution by nebulizer every 6-8 hr PRN.
Children:
- 1-11 months: 1-2 ml of 20% or 2-4 ml of 10% solution by nebulizer every 6-8 hr PRN.
- 12 months-11 years: 3-5 ml of 20% or 6-10 ml of 10% solution by nebulizer every 6-8 hr PRN.
- Below 12 years: 5-10 ml of 10/20% solution by nebulizer every 6-8 hr PRN.
Diagnostic Bronchograms: 1-2 ml of 20% or 2-4 ml of 10% solution 2-3 times by nebulization or by instillation intratracheally prior to procedure.
Nebulization tent or croupette: This form of administration requires very large volumes of the solution, occasionally as much as 300 ml during a single treatment period. If a tent or croupette must be used, the recommended dose is the volume of acetylcysteine (using 20%) that will maintain a very heavy mist in the tent or croupette for the desired period. Administration for intermittent or continuous prolonged periods, including overnight, may be desirable.
Direct Instillation: When used by direct instillation, 1-2 ml of a 20% solution may be given as often as every hour. When used for the routine nursing care of patients with tracheostomy, 1-2 ml of a 20% solution may be given every 1-4 hours by instillation into the tracheostomy.
Side Effects
Generally, DA Hoestbruistabletten Acetylcysteïne is well tolerated. However, mild effects such as nausea, headache, tinnitus, urticaria, stomatitis, rhinorrhoea, chills, fever, bronchospasm may be observed. Occasional cases of nausea and dyspepsia, rare cases of urticaria may be observed.
Toxicity
Patients experiencing an overdose may present with vomiting, nausea, bronchospasm, periorbital angioedema, and hypotension. Treat patients with symptomatic and supportive measures. Hemodialysis may remove some acetylcysteine from circulation as it is somewhat protein bound.
Precaution
DA Hoestbruistabletten Acetylcysteïne should be given in caution in asthma patients.
Interaction
After taking DA Hoestbruistabletten Acetylcysteïne orally it increases the bioavailability of Amoxicillin, but shows no effect on Doxycycline and reduces the absorption of Cefalexin. DA Hoestbruistabletten Acetylcysteïne seems to increase the effects of Nitroglycerin.
Food Interaction
No interactions found.DA Hoestbruistabletten Acetylcysteïne Disease Interaction
Major: hepatic encephalopathyModerate: asthma, fluid overload, gastric hemorrhage
Volume of Distribution
The volume of distribution of acetylcysteine is 0.47 L/kg.
Elimination Route
An 11 g dose in the form of an effervescent tablet for solution reaches a mean Cmax of 26.5 µg/mL, with a Tmax of 2 hours, and an AUC of 186 µg*h/mL.
Half Life
The mean terminal half life of acetylcysteine in adults is 5.6 hours and in pre-term neonates is 11 hours.
Clearance
DA Hoestbruistabletten Acetylcysteïne has a mean clearance of 0.11 L/hr/kg.
Elimination Route
An oral dose of radiolabelled acetylcysteine is 13-38% recovered in the urine in the first 24 hours, while 3% is recovered in the feces.
Pregnancy & Breastfeeding use
Pregnancy Category B. Caution should be taken in case of pregnancy & lactation while using DA Hoestbruistabletten Acetylcysteïne.
Contraindication
Known hypersensitivity to active ingredient. Also contraindicated in patients suffering from phenylketonuria and peptic ulcer.
Acute Overdose
Accidental overdose of DA Hoestbruistabletten Acetylcysteïne may cause nausea, vomiting or diarrhea.
Storage Condition
Protect from light & moisture, store below 25° C. Keep all medicines out of the reach of children.
Innovators Monograph
You find simplified version here DA Hoestbruistabletten Acetylcysteïne
DA Hoestbruistabletten Acetylcysteïne contains Acetylcysteine see full prescribing information from innovator DA Hoestbruistabletten Acetylcysteïne Monograph, DA Hoestbruistabletten Acetylcysteïne MSDS, DA Hoestbruistabletten Acetylcysteïne FDA label
FAQ
What is DA Hoestbruistabletten Acetylcysteïne?
DA Hoestbruistabletten Acetylcysteïne (Acetylcysteine) also known as N-acetylcysteine (NAC), is a medication that is used to treat paracetamol (acetaminophen) overdose, and to loosen thick mucus in individuals with chronic bronchopulmonary disorders like pneumonia and bronchitis. It can be taken intravenously, by mouth, or inhaled as a mist.
What is DA Hoestbruistabletten Acetylcysteïne used for?
DA Hoestbruistabletten Acetylcysteïne inhalation is used along with other treatments to relieve chest congestion due to thick or abnormal mucous secretions in people with lung conditions including asthma, emphysema, bronchitis and cystic fibrosis (an inborn disease that causes problems with breathing, digestion, and reproduction).
What are the side effects of DA Hoestbruistabletten Acetylcysteïne?
DA Hoestbruistabletten Acetylcysteïne is Likely safe for most adults. It can cause nausea, vomiting, and diarrhea or constipation. Rarely, it can cause rashes, fever, headache, drowsiness, low blood pressure, and liver problems.
Who should not take DA Hoestbruistabletten Acetylcysteïne?
If you have asthma or bleeding problems, your doctor may tell you to avoid DA Hoestbruistabletten Acetylcysteïne. You will likely be told to stop DA Hoestbruistabletten Acetylcysteïne 2 weeks before any elective surgery. If you're pregnant or breastfeeding, you must check with a doctor before using DA Hoestbruistabletten Acetylcysteïne supplements.
How long does DA Hoestbruistabletten Acetylcysteïne take to work?
The study showed that DA Hoestbruistabletten Acetylcysteïne significantly reduced the symptoms of trichotillomania compared to a placebo. 56% of subjects reported "much or very much improved" on DA Hoestbruistabletten Acetylcysteïne compared to 16% on placebo (sugar pill or inert substance). Significant improvement was initially noted after 9 weeks of treatment.
When is the best time to take DA Hoestbruistabletten Acetylcysteïne?
Single amino acid supplements, like DA Hoestbruistabletten Acetylcysteïne, are best taken on an empty stomach. The absorption of amino acids can be affected by the foods you take them with and by other amino acids.
Is DA Hoestbruistabletten Acetylcysteïne safe to take daily?
There is no recommended daily allowance for DA Hoestbruistabletten Acetylcysteïne, because unlike vitamins, it's not an essential nutrient. The dosage used to prevent radio contrast dye damage is 600 mg to 1200 mg every 12 hours for 48 hours.
What are the benefits of taking DA Hoestbruistabletten Acetylcysteïne?
Classic mucolytic drugs such as DA Hoestbruistabletten Acetylcysteïne decrease the viscoelastic properties of mucus by reducing disulfide bonds. In contrast, expectorants change mucus consistency and make coughing more productive, mucokinetics improve transportability, and mucoregulators suppress mucus secretion.
Does DA Hoestbruistabletten Acetylcysteïne really work?
DA Hoestbruistabletten Acetylcysteïne supplements have been used to improve COPD symptoms, exacerbations and lung decline. In a one-year study, 600 mg of DA Hoestbruistabletten Acetylcysteïne twice a day significantly improved lung function and symptoms in those with stable COPD. Those with chronic bronchitis can also benefit from DA Hoestbruistabletten Acetylcysteïne.
Is DA Hoestbruistabletten Acetylcysteïne safe in pregnancy?
Animal studies did not show teratogenicity; slightly decreased fertility was seen at doses above the maximum human dose. Limited case reports did not report any adverse fetal or neonatal outcomes. This drug crosses the placenta and was measurable in the serum of the infant. Pregnant women should be managed the same way as nonpregnant patients for acetaminophen overdose, and that acetylcysteine therapy was protective to both mother and fetus. There are no controlled data in human pregnancy. Use is not recommended unless clearly needed.
Is DA Hoestbruistabletten Acetylcysteïne safe during Breastfeeding?
Animal studies did not show adverse effects during lactation. It is unknown in this drug or its metabolites are excreted in milk. Based on the pharmacokinetics, it should be nearly cleared 30 hours after administration. Use is not recommended.
